A blockbuster unleashed: What happens when a big fat business explodes?

India is about to get a lot thinner, and a lot more complicated. The expiry of Novo Nordisk’s patent on semaglutide, the molecule powering blockbuster drugs like Ozempic and Wegovy, is set to unleash a tidal wave of cheap copies across the country. What was until now a premium treatment for the urban wealthy could soon become a mass-market product, prescribed in clinics, requested at pharmacies and discussed in everyday conversations. But as prices crash and access explodes, the real story is not just about affordability. It is about a healthcare system bracing for a surge in demand, a pharmaceutical industry gearing up for a fierce battle and regulators confronting the risks of a drug that sits uncomfortably between life-saving therapy and lifestyle shortcut.

Also read: The weight is over. This injectable fits the bill

A flood of generics and a new competitive era

The immediate impact of the patent expiry is a surge of domestic competition. More than 40 Indian pharmaceutical firms are expected to launch over 50 brands of semaglutide within weeks. Companies such as Sun Pharma, Mankind Pharma, Dr Reddy’s, Zydus, Lupin and Alkem are preparing aggressive entries into the market. At least six to seven firms plan to launch products on day one, with many more expected to follow in the coming months. This rapid influx reflects the Indian pharmaceutical industry’s strength in reverse engineering and scaling generics quickly.

For multinational innovators like Novo Nordisk and Eli Lilly, which only recently introduced these therapies in India, this creates an immediate competitive squeeze. Lilly’s Mounjaro had already become India’s top-selling drug by value within months of launch, underlining the size of the opportunity now being contested.

The price collapse that changes everything

The most consequential shift will be in pricing. Semaglutide therapies, previously priced for a narrow urban elite, are set to become dramatically more affordable. Reuters reports that monthly costs could fall from around Rs 11,000 to Rs 3,000–5,000 in the early phase, eventually dropping further to Rs 1,500-2,500 as competition intensifies. A TOI story estimates a roughly 50% price cut initially, with starting doses expected around Rs 3,500-4,000 per month.

This sharp decline is likely to unlock demand on a massive scale. As one Hyderabad-based patient told Reuters, he is considering switching to generics because they are “lighter on the pocket.” Doctors are already seeing patients delay treatment in anticipation of cheaper options. Analysts go even further, suggesting that the market could grow tenfold over the next few years as affordability improves.

Also read: Obesity bet may drive focus on chronic segment

Expanding access beyond the urban elite

Lower prices will fundamentally broaden access. India’s healthcare system is largely out-of-pocket, making affordability the primary determinant of treatment uptake. As per a Reuters report, India already has the world’s second-largest diabetic population and could see over 440 million overweight or obese individuals by 2050. In this context, semaglutide’s transition from a premium therapy to a mass-market drug could significantly expand the treated population. Pharmarack’s Sheetal Sapale told Reuters that “onboarding of patients from lower economic strata may happen on branded generics,” pointing to a shift from niche to mainstream adoption.

The current Rs 1,400 crore weight-loss market could double within a year, as per TOI. This expansion is not just incremental growth but the unlocking of previously suppressed demand.

A prescription boom, but also the risk of misuse

However, wider access brings new risks. There are concerns about misuse, especially in a market where prescription enforcement can be inconsistent. Analyst Salil Kallianpur told Reuters that falling prices and high demand could lead to “direct pharmacy purchases, distributor-level leakages, or cosmetic or lifestyle use, especially in urban markets.” He added that this may result in “misuse, poor titration and unmanaged side effects and eventually regulatory tightening.”

Semaglutide is a prescription drug, but in India, pharmacists and informal channels often act as de facto gatekeepers. The sudden availability of dozens of brands may make oversight more difficult.

Doctors are also likely to face a surge in demand from patients seeking weight-loss solutions rather than strictly medical treatment, blurring the line between therapy and lifestyle use.

Also read: Novo to track generic surge as semaglutide goes off patent

Doctors as kingmakers in a crowded market

Despite the flood of brands, price alone will not determine winners. India’s pharmaceutical market is deeply influenced by physician trust. Doctors may initially be overwhelmed by the sheer number of options, especially as many brands incorporate “sema” in their names, adding to confusion. Over time, prescribing patterns are expected to consolidate around a smaller set of trusted players. Kallianpur said that weaker firms with poor quality or differentiation are likely to exit within two to three years. This suggests that the current explosion of competition may eventually give way to a more stable hierarchy.

The importance of delivery systems also matters. As Sun Pharma’s managing director Kirti Ganorkar told TOI, the company plans to offer its product in “an easy-to-use prefilled pen format” and ensure sufficient supply, highlighting that convenience and reliability will be key differentiators.

Industry upside

For Indian pharmaceutical companies, the patent expiry represents a major commercial opportunity. Firms are investing heavily in manufacturing, device platforms and field force expansion. Companies are forming partnerships and expanding sales teams in anticipation of demand. Neeraj Sharma of OneSource Specialty Pharma told TOI, “We believe the entry of generic semaglutide will unlock significant latent demand, providing a strong boost to an already expanding market.”

This could also reinforce India’s global reputation as a supplier of affordable generics, particularly in complex biologic and injectable therapies. At the same time, profit margins will depend on pricing discipline. As competition intensifies, companies may face pressure to balance volume growth with profitability.

Public health impact: Promise and complexity

From a public health perspective, the implications are profound. On one hand, greater access to effective diabetes and obesity treatments could help address two of India’s most pressing health challenges. On the other hand, the potential for misuse, inconsistent dosing and uneven quality raises concerns about safety and long-term outcomes. Without strong regulatory oversight and physician guidance, the benefits of wider access could be diluted. The likely trajectory is a cycle where rapid expansion is followed by regulatory tightening once risks become evident.

The beginning of a long transition

The expiry of the semaglutide patent is not a one-time event but the beginning of a structural shift. In the short term, India will see a chaotic surge of brands, aggressive pricing and explosive demand. In the medium term, the market will consolidate around trusted players. In the long term, semaglutide could become a widely used therapy across income groups.

What is clear is that this is no ordinary pharmaceutical transition. It sits at the intersection of chronic disease, consumer aspiration and industrial competition. In a country where affordability shapes access, the fall in prices could turn a once-exclusive drug into a mass-market phenomenon.

Whether that translates into better health outcomes or a new wave of misuse will depend on how effectively India manages the balance between access and oversight.